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INTRODUCTION
 Sarcopenia is the progressive and generalized 
loss of skeletal muscle
 It’s significance is increasingly recognized and 
reported within the surgical and medical 
oncology fields
 It is now reported as an independent predictor 
of clinical outcomes in multiple gastrointestinal 
cancers
 Sarcopenia is being explored in surgical and 
medical oncology as a prognostic factor before 
treatment 
 This study evaluated whether sarcopenia could 
be prognostic for grade 3 or greater toxicity, 
pathologic response, or overall survival  in 
patients treated neoadjuvantly for esophageal 
cancer
METHODS
 Moffitt esophageal cancer patients treated 
with neoadjuvant chemoradiation followed by 
surgery from 2008-2012
 All patients received IMRT/IGRT utilizing dose 
painting to a total dose of 50.4/56 Gy in 28 
fractions along with cisplatin and 5FU 
chemotherapy 
 Sarcopenia was defined as the presence of a 
psoas area less than the median of the cohort 
 ROC curve, logistic regression, chi square and 
Kaplan Meier estimates were used when 
appropriate
Eligibility Criteria
 CT imaging for planning including the L4 
vertebral body







No. of patients (%)
P
Total Patients 23 33




Male 14 (25%) 33 (59%) <0.001




Not pathCR 11 (20%) 17 (30%) 0.786
pathCR




TRG 2/3 3 (5%) 7 (13%) 0.432
TRG 0/1
20 (36%) 26 (46%)
Acute 
Toxicity
Grade ≤2 8 (14%) 25 (45%) 0.002
Grade 3+
15 (27%) 8 (14%)
 Sarcopenia was predictive of 
– Grade 3 Toxicity
 The smaller the psoas cross sectional area, 
the higher the chance of any grade 3 toxicity 
 Patients below our cutoff were 5.86 times 
more likely to develop a grade 3 or higher 
toxicity (p=0.003)
 Sarcopenia was not predictive of
– Pathologic Response 
– Overall Survival (p=0.124)
T1. Patient Characteristics
Sarcopenic Non-sarcopenic
Total Patients 23 33












F1. ROC Analysis of Grade 3+ Toxicity
F2. Kaplan Meier Curve for Overall Survival
T2. Toxicity
CONCLUSIONS / FUTURE DIRECTIONS
Sarcopenia may be a useful prognostic marker for 




• Quality of life benefit
• Further Validation 
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